How Masteron Affects LDL Cholesterol

Drostanolone propionate's LDL profile is predicted by two competing structural features, neither of which has been measured in humans:

1. Injectable and non-alkylated, which protects LDL: Thompson (1989, PMID 2915439) established that route of administration is what determines whether an androgen raises LDL. Oral stanozolol raised LDL 29% while intramuscular testosterone in the same men lowered it 16%. Masteron sits firmly on the injectable side of that divide, so the mechanism that drives large LDL rises in oral steroids is largely absent.

2. Non-aromatising, which hurts: Oestradiol upregulates hepatic LDL receptor expression, which is the pathway that clears LDL from plasma. Masteron produces none of its own oestradiol. The relevant comparison is nandrolone, which is also injectable, non-alkylated and weakly aromatising, and which showed no significant LDL change in two randomised trials (Sattler 2002, PMID 12388173, Hartgens 2004, PMID 15155420). That is the strongest argument that masteron is unlikely to be a major LDL driver.

3. DHT derivatives and hepatic androgen signalling: Drostanolone binds the androgen receptor as a DHT derivative, and androgen receptor signalling at the hepatocyte is what downregulates LDL receptor expression. Whether an injectable DHT derivative produces enough of that signal to move LDL measurably is unknown.

4. What is likely happening in real bloodwork: masteron is a stacking compound. An LDL rise on a masteron-containing cycle almost always has an oral compound or an aggressive aromatase inhibitor as its more plausible cause.

There is no human lipid trial of drostanolone at any dose. Its clinical era was breast carcinoma treatment in the 1960s and 1970s, and the lipid measurements now considered standard were not routinely made.

What the closest comparators show:

• Nandrolone, injectable and non-alkylated: no significant change in total cholesterol, LDL cholesterol or LDL phenotype on high-dose administration for 12 weeks (Sattler 2002, PMID 12388173); no significant change in any lipid or apolipoprotein at 200 mg/week for 8 weeks (Hartgens 2004, PMID 15155420).
• Testosterone, injectable and aromatising: LDL down 16% (Thompson 1989, PMID 2915439) and down 5 mg/dL across 272 hypogonadal men (Whitsel 2001, PMID 11566455).
• Oral stanozolol: LDL up 29% at 6 mg/day.

Practical expectation at typical doses (300-600 mg/week):

• LDL close to baseline, or modestly raised.
• HDL is the marker that will move on masteron, and non-HDL cholesterol will worsen mainly because of that.
• If LDL is substantially elevated on a masteron cycle, look at the oral compounds and the aromatase inhibitor before attributing it here.

Timing: The propionate ester reaches steady state within a week. Check lipids at week 4.

Baseline lipid panel before the whole cycle: masteron is added to a stack, so a mid-cycle baseline will not isolate anything.

On cycle:

• Lipids at week 4, including HDL, LDL, total cholesterol and triglycerides.
• ApoB if available. It is the better marker when HDL is falling and calculated LDL becomes less reliable.
• Track non-HDL cholesterol, which captures both sides.

Attribution matters here more than most compounds:

• Masteron is structurally among the less likely compounds in a typical stack to raise LDL.
• Oral 17-alpha-alkylated compounds have measured effects of 29% or more. An aggressive aromatase inhibitor removes hepatic LDL receptor support. Both are more probable explanations.

Contest prep confounders: very low body fat, extreme dieting and diuretics all shift the lipid panel in the weeks masteron is typically used. Interpret results in that context.

Post-cycle: Recheck at 8 weeks.

Look elsewhere for the LDL problem:

• If lipids are the reason for a protocol change, dropping an oral achieves far more than dropping the masteron.
• Do not crush oestradiol. Masteron contributes none, so all of it comes from your testosterone base, and it is the only hepatic LDL receptor support in the protocol.

Standard measures:

• Soluble fibre 10 to 25 g/day lowers LDL through bile acid sequestration, a pathway unaffected by anything in the stack.
• Replacing saturated fat with unsaturated fat works normally.
• Cardiovascular exercise 30 to 45 minutes, 4 to 5 times per week, primarily for HDL.
• Omega-3 at 3 to 4 g/day for triglycerides rather than LDL.

Test, because there is no literature to fall back on: With an unstudied compound, your own serial panels are the only evidence available. A pre-cycle and week-4 panel costs very little relative to the alternative of guessing.

Further reading: What steroids actually do to your cholesterol